1. Home
  2. PMCB vs NVNO Comparison

PMCB vs NVNO Comparison

Compare PMCB & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.44

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Logo enVVeno Medical Corporation

NVNO

enVVeno Medical Corporation

N/A

Current Price

$8.67

Market Cap

6.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PMCB
NVNO
Founded
1996
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.3M
6.2M
IPO Year
2001
2017

Fundamental Metrics

Financial Performance
Metric
PMCB
NVNO
Price
$0.44
$8.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 302.6K
23.4K
Earning Date
03-17-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $31,243.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$140.00
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.30
52 Week High
$1.51
$13.44

Technical Indicators

Market Signals
Indicator
PMCB
NVNO
Relative Strength Index (RSI) 44.03 33.78
Support Level $0.33 $7.01
Resistance Level $0.77 $11.47
Average True Range (ATR) 0.05 0.75
MACD 0.01 -0.14
Stochastic Oscillator 63.10 34.51

Price Performance

Historical Comparison
PMCB
NVNO

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: